alexa Pharmacokinetic Changes Secondary to Roux en Y Gastric Bypass

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Pharmacokinetic Changes Secondary to Roux en Y Gastric Bypass

Obesity is a growing epidemic leading to world-wide public health concerns. In 1999–2000, 27.5% of men and 33.4% of women were obese. The prevalence increased to 35.5% in men and 35.8% in women by 2009–2010. Bariatric surgery is an excellent option for patients with clinically severe obesity, defined as body mass index (BMI) of greater than 40 or BMI of >35 with serious comorbid conditions.

 

 

Citation: Giuliano C, Wilhelm SM, Kale-Pradhan PB (2012) Pharmacokinetic Changes Secondary to Roux en Y Gastric Bypass. Adv Pharmacoepidem Drug Safety S1:001. doi: 10.4172/2167-1052.S1-001

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top